Heparin Market Size, Share & Industry Analysis, By Product (Unfractionated Heparin (UFH) and Low Molecular Weight Heparin (LMWH)), By Source (Bovine and Porcine), By Application (Deep Vein Thrombosis & Pulmonary Embolism, Atrial Fibrillation, Heart Attacks, Stroke, and Others), By Route of Administration (Intravenous Infusion and Subcutaneous Injection), By End-User (Hospitals & ASCs, Clinics, and Others), and Regional Forecast, 2025-2032

The global heparin market size was valued at USD 10.21 billion in 2024. The market is projected to grow from USD 10.62 billion in 2025 to USD 14.52 billion by 2032, exhibiting a CAGR of 4.57% during the forecast period.

The heparin market is witnessing a noteworthy growth trajectory during the forecast period. Heparins are a class of first-line anticoagulant drugs used to prevent blood clotting. They work by inhibiting the activity of clotting factors in the blood, thus preventing and treating blood clots in various disease conditions and during surgical procedures. These products are typically administered through subcutaneous injections or intravenous infusion to reduce the risk of deep vein thrombosis, pulmonary embolism, or during surgeries.

Furthermore, the prevalence of complications associated with cardiovascular diseases, such as stroke and thrombosis, increases the demand for heparin-based anti-coagulants.

• For instance, in January 2025, as per the CDC, venous thromboembolism (VTE) affects as many as 900,000 people in the U.S. every year.

Additionally, key players in the market, such as Sanofi and Pfizer Inc., as well as LEO Pharma A/S, offer prominent products, including low molecular weight heparin (LMWH), and engage in strategic activities to support their dominance in the market.

MARKET DYNAMICS

MARKET DRIVERS

Increased Incidences of Cardiovascular and Other Chronic Disorders to Drive Market Growth

The rising prevalence of cardiovascular diseases, thrombosis, and embolism is one of the most prominent driving factors of the market. Rising aging population, lifestyle modification leading to increased risk of cardiovascular diseases. Heparin is a critical, life-saving drug that is often administered in several life-threatening medical conditions or scenarios, thus boosting the demand for these products in the market. 

• For instance, according to the American Heart Foundation, around 5.0 million people in America are estimated to be living with AF, and more than 12.0 million people are projected to have it by 2030. The high number of deceased individuals increases demand for the product, propelling the global heparin market growth.

MARKET RESTRAINTS

Shortage of Raw Materials and Safety Concerns from Animal-Derived Products to Restrain Market Growth

The market is totally dependent on animal-sourced raw material from porcine and bovine mucosa. The majority of the market depends on raw materials from China, as it is the major distributor of porcine intestinal mucosa globally. However, due to disease outbreaks such as African swine fever ASF, the pig population gets hampered and leading to a shortage in the raw material supply.

• For instance, in June 2025, an ASF outbreak occurred in a village in Napo County, Baise City, Guangxi Zhuang Autonomous Region, leading to the death of 200 pigs and the culling of 586 pigs.

MARKET OPPORTUNITIES

Advancement in Development of Heparin Sources to Offer Lucrative Growth Opportunities

The traditional heparin raw material sources have a risk of transmitting zoonotic diseases and are derived from biological sources. Thus, to enhance the supply of raw materials and reduce reliance on porcine mucosa from single-country sources, researchers are developing next-generation bioengineered and chemoenzymatic heparin.

This development is expected to improve the quality, regulatory confidence, and ethical acceptance, thus offering a lucrative opportunity for the market to grow.

• For instance, in May 2024, the School of Pharmaceutical Sciences at Shandong University, Jinan, China, is developing bioengineered heparin for medical use.

HEPARIN MARKET TRENDS

Launch of Technologically Advanced Heparin to Support Market Growth

The launch of technologically advanced heparin products is a significant global trend in the market. It is a lifesaving drug in emergencies; thus, manufacturers are focusing on developing and launching easy-to-use, convenient, and more effective formulations to meet increasing clinical demands.

Additionally, increasing focus on regulatory approvals and increased R&D investments are facilitating the introduction of novel heparin solutions. Thus, shaping the future landscape of the heparin industry.

• For instance, in March 2023, Techdow USA Inc. received the U.S. FDA approval for its Enoxaparin Sodium in pre-filled syringes for the U.S. market.

MARKET CHALLENGES

Ethical and Religious Concerns to Impede Product Adoption and Market Growth

In the Muslim-majority communities where pork-based products are banned to use due to ethical and religious reasons, this hampers the adoption of porcine mucosa-based heparin in this population. However, religious authorities often permit porcine heparin only in emergencies without alternatives.

• For instance, in August 2024, as reported in the Journal of the British Islamic Medical Association, due to religious restrictions, the current clinical practice often substitutes heparin with fondaparinux for Muslim patients.

Download Free sample to learn more about this report.

Segmentation Analysis

By Product

Increasing Approval for Low Molecular Weight Heparin (LMWH) to Boost Segment’s Growth

On the basis of the segmentation of the product, the market is classified into unfractionated heparin (UFH) and low molecular weight heparin (LMWH).

The low-molecular-weight heparin segment held the largest global heparin market share in 2024. The dominant share of the segment is attributed to the advantages of low molecular weight heparin (LMWH), including better safety features, a predictable anticoagulant response, and the availability of subcutaneous administration. Additionally, the increasing approval of these products by regulatory bodies is driving the segment’s growth.

• In December 2020, Valeo Pharma announced that Health Canada had approved the company’s low-molecular-weight heparin (LMWH) biosimilars, Redesca and Redesca HP.

To know how our report can help streamline your business, Speak to Analyst

By Source

Robust Presence of Porcine Mucosa as Raw Material to Bolster Segment’s Growth

In terms of source, the market is categorized into bovine and porcine.

The porcine segment accounted for the largest market share. In 2025, the segment is anticipated to dominate with a 94.6% share. The dominant share of the segment is attributed to the strong presence of porcine-sourced heparin products, which have experienced robust global adoption.

• According to a news article published in The Economic Times in September 2020, India has been importing crude heparin from China, which accounts for nearly 60.0% of the world's pig production.

The bovine segment is expected to grow at a CAGR of 3.10% over the forecast period. 

By Application

Increasing Incidence of Heart Attacks to Boost the Segments' Growth

Based on the application, the market is divided into deep vein thrombosis & pulmonary embolism, atrial fibrillation, heart attacks, stroke, and others.

The heart attack segment held the dominating market position in 2024. By application, the heart attack segment held a 33.3% share in 2024. The dominant share of the segment is due to the increasing prevalence of heart attacks globally due to lifestyle changes, sedentary lifestyles, and a rising geriatric population, thus increasing the demand for heparin worldwide.

• For instance, as per the CDC, every year about 805,000 people in the U.S. have a heart attack. Such a high incidence of the disease increases the demand for heparin in emergencies.

The atrial fibrillation segment is expected to grow at a CAGR of 4.85% over the forecast period. 

By Route of Administration

Wide Availability and Ease of Administration to Drive Subcutaneous Injection Segments' Growth

Based on route of administration, the market is segmented into intravenous infusion and subcutaneous injection.

The subcutaneous injection segment held the dominating market position in 2024. By route of administration, the subcutaneous injection segment held a 54.1% share in 2024. The dominant share of the segment is attributed to the increasing prevalence of cardiovascular diseases and the ease of administration in home care settings, thereby eliminating the need for constant monitoring.

The intravenous infusion segment is poised for growth, with a forecasted growth rate of 3.86% across the global market during the forecast period. Increasing product launches associated with intravenous infusion to boost the segment’s growth during the forecast period.

• In February 2024, B. Braun SE launched new Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL), the fifth product in its portfolio of Heparin premixed bags.

By End-User

Increasing Emergency Admission to Propel Hospitals & ASCs Segments Growth

Based on end user, the market is segmented into hospitals & ASCs, clinics, and others.

In 2024, the hospitals & ASCs segment is expected to witness a leading growth trajectory. The segment is set to hold 55.4% share in 2025.  The increasing adoption of heparin in emergency situations and the rising number of hospital admissions are expected to boost the adoption of heparin in these settings.

• For instance, in May 2024, as per the CDC, more than 454,000 hospitalizations with atrial fibrillation as the primary diagnosis happen each year in the U.S.

Additionally, clinics are projected to grow as an end-user at a CAGR of 4.93% during the study period.

Heparin Market Regional Outlook

By region, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant share in 2024, valued at USD 5.23 billion, and also maintained the leading share in 2025 with USD 5.45 billion. North America’s dominance in the market is driven by factors such as the increasing prevalence of stroke and heart attacks, as well as the rising adoption of porcine-based heparin. In 2025, the U.S. market is estimated to reach USD 5.04 billion. The U.S. is expected to dominate the North America region's market, owing to the increasing demand for heparin and the focus of major players on expanding their footprint in the U.S. market to boost growth.

• For instance, in March 2023, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. received abbreviated new drug application (ANDA) approval for its enoxaparin sodium injection from the U.S. FDA.

Europe and Asia Pacific

Europe and the Asia Pacific are expected to experience notable growth in the coming years. During the forecast period, the European region is projected to record a growth rate of 4.31%, the second-highest among all regions, and reach a valuation of USD 2.27 billion by 2025. The increasing prevalence and demand for heparin primarily drive the growth. Backed by these factors, countries including the U.K. are expected to record the valuation of USD 0.41 billion, Germany to record USD 0.61 billion, and France to record USD 0.42 billion in 2025. After Europe, the Asia Pacific market is projected to reach USD 1.77 billion by 2025, securing the position of the third-largest region in the market. In the region, India and China are both estimated to reach USD 0.23 billion and USD 0.57 billion, respectively, in 2025.

Latin America and Middle East & Africa

Over the forecast period, the Latin America and the Middle East & Africa regions would witness a moderate growth in this market. The Latin America market in 2025 is expected to reach a valuation of USD 0.62 billion. The growth of the region is owing to the gradual adoption of the advanced heparin for the treatment of cardiovascular diseases. In the Middle East & Africa, the GCC is set to reach a value of USD 0.22 billion by 2025.

COMPETITIVE LANDSCAPE

Expansion of Product Offering and Strong Initiatives to Maintain Their Position

The global market exhibits a semi-consolidated structure, with large companies actively operating globally. These players have a robust product portfolio for finished heparin with advanced product offerings such as LMWH.

Sanofi and Pfizer Inc. are some of the dominant players in the market. The company offers a comprehensive, strong, and advanced product for heparin with a safe and effective profile.

Apart from this, other prominent players in the market include LEO Pharma A/S, Baxter, and Hepalink Group, among other major key players. These key players are focusing on offering unfractionated as well as LMWH advanced products to enhance their market presence.

LIST OF KEY HEPARIN COMPANIES PROFILED

• Opocrin S.p.A. (Italy)
• Baxter (U.S.)
• Pfizer Inc. (U.S.)
• Bioiberica S.A.U. (Spain)
• Fresenius SE & Co. KGaA (Germany)
• Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (China)
• Braun SE (Germany)
• Reddy’s Laboratories Ltd. (India)
• LEO Pharma A/S (Denmark)
• Aspen Holdings (South Africa)
• Sanofi (France)

KEY INDUSTRY DEVELOPMENTS

• June 2024- Laboratorios Farmacéuticos ROVI, S.A. has completed the expansion of its plant in Escúzar, Granada, and installed a new sodium heparin production line. This plant aimed to produce low-molecular-weight heparin (LMWH) operations.
• October 2023 - Sanofi announced the shipment of Enoxaparin Sodium Impact, an anticoagulant used to treat venous thromboembolism, including deep vein thrombosis, in Africa. 
• June 2023:  Biological E. Limited (BE) received U.S. FDA approval for Enoxaparin Sodium (LMWH) single-dose pre-filled syringes for prophylaxis of deep vein thrombosis in various surgeries and conditions.
• March 2022: Hepalink Group announced the approval of heparin sodium and enoxaparin sodium APIs in India, aiming to expand its distribution channel.
• September 2019: Hikma Pharmaceuticals PLC announced the launch of the Heparin Sodium prefilled syringes in the U.S.

REPORT COVERAGE

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation